The issue of renal safety of zoledronic acid from a nephrologist's point of view

被引:23
作者
Balla, J
机构
[1] Univ Debrecen, Med & Hlth Sci Ctr, Dept Nephrol, H-4012 Debrecen, Hungary
[2] Univ Debrecen, Med & Hlth Sci Ctr, Hemodialisys Unit, H-4012 Debrecen, Hungary
关键词
D O I
10.1634/theoncologist.10-5-306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:306 / 308
页数:3
相关论文
共 24 条
[11]   American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer [J].
Hillner, BE ;
Ingle, JN ;
Berenson, JR ;
Janjan, NA ;
Albain, KS ;
Lipton, A ;
Yee, G ;
Biermann, JS ;
Chlebowski, RT ;
Pfister, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (06) :1378-1391
[12]  
LEVEY AS, 1988, ANNU REV MED, V39, P465, DOI 10.1146/annurev.med.39.1.465
[13]   National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification [J].
Levey, AS ;
Coresh, J ;
Balk, E ;
Kausz, AT ;
Levin, A ;
Steffes, MW ;
Hogg, RJ ;
Perrone, RD ;
Lau, J ;
Eknoyan, G .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (02) :137-147
[14]  
LEVEY AS, 1993, J AM SOC NEPHROL, V4, P1159
[15]   A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation [J].
Levey, AS ;
Bosch, JP ;
Lewis, JB ;
Greene, T ;
Rogers, N ;
Roth, D .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :461-+
[16]   Toxic acute tubular necrosis following treatment with zoledronate (Zometa) [J].
Markowitz, GS ;
Fine, PL ;
Stack, JI ;
Kunis, CL ;
Radhakrishnan, J ;
Palecki, W ;
Park, J ;
Nasr, SH ;
Hoh, S ;
Siegel, DS ;
D'Agati, VD .
KIDNEY INTERNATIONAL, 2003, 64 (01) :281-289
[17]  
Markowitz GS, 2001, J AM SOC NEPHROL, V12, P1164, DOI 10.1681/ASN.V1261164
[18]  
Pecherstorfer M, 1996, J BONE MINER RES, V11, P587
[19]   The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats [J].
Pfister, T ;
Atzpodien, E ;
Bauss, F .
TOXICOLOGY, 2003, 191 (2-3) :159-167
[20]  
Rosen LS, 2001, CANCER J, V7, P377